Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06450873 · ClinicalTrials.gov registry record · Phase 2
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
A Phase 2 study of HER2-Negative Breast Carcinoma and Estrogen Receptor-Positive Breast Carcinoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06450873: Recruiting Phase 2 study of HER2-Negative Breast Carcinoma and Estrogen Receptor-Positive Breast Carcinoma, sponsored by Mayo Clinic.
NCT06450873 is a Phase 2 study of HER2-Negative Breast Carcinoma and Estrogen Receptor-Positive Breast Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 430-participant average among 18 other HER2-Negative Breast Carcinoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06450873, a Phase 2 study of HER2-Negative Breast Carcinoma and Estrogen Receptor-Positive Breast Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins, as well as for cancer, hepatitis, and infections. There is previous evidence of significant tumor shrinkage occurring in the 2-month window between diagnosis and surgery in women who have taken TTM. Giving TTM may be effective in treating post-menopausal women with HER2-negative, ER-positive breast cancer undergoing surgery.
Primary Outcome
Change in Ki-67 from the time of enrollment (pre-treatment) to the time of surgery (post-treatment) will be recorded. Slides from the original biopsy at the time of diagnosis will be used to assess pre-treatment Ki-67. A tissue sample obtained at the time of surgery will be used to assess Ki-67 post-treatment.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- DRUG Coriolus Versicolor Extract
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
What NCT06450873 shows while recruiting
NCT06450873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 430-participant average among 18 other HER2-Negative Breast Carcinoma trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with HER2-Negative Breast Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Questionnaire Administration is the first listed.
NCT06450873 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT06450873 about?
NCT06450873 is a clinical study titled "Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery". This phase II trial tests how well turkey tail mushroom (TTM) works in treating post-menopausal women with HER2-negative, estrogen receptor (ER)-positive breast cancer undergoing surgery. TTM is a common mushroom. In traditional Chinese medicine, it is used for enhancing function and removing toxins...
What is the current status of trial NCT06450873?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-10-25. Estimated completion is 2028-04-30.
What conditions does trial NCT06450873 study?
This clinical trial studies the following conditions: HER2-Negative Breast Carcinoma, Estrogen Receptor-Positive Breast Carcinoma.
What interventions are being tested in trial NCT06450873?
The interventions under investigation include: Questionnaire Administration (OTHER), Coriolus Versicolor Extract (DRUG).
Who is sponsoring clinical trial NCT06450873?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06450873 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-Negative Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06450873's enrollment target sits among peer trials
40 15th of 18 higher than 2 of 18 other HER2-Negative Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2-Negative Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
RECRUITING · Phase 2
-
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
RECRUITING · Phase 2
-
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
RECRUITING · Phase 2
-
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
RECRUITING · Phase 3
-
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
RECRUITING · NA
-
Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI